Summary (1)

• Overall SVR of 61% in patients treated for 48 weeks with PEGASYSÆ and RBV 1000/1200 mg

• Overall safety profile similar to previous studies

Previous slide

Next slide

Back to first slide

View graphic version

To re-state that for

geno 1: efficacy falls if reduce duraton or RBV dose

non-1: increasing duration and/or RBV dose has no benefit in efficacy